Publications associées à Tissue Factor-Independent Coagulation Correlates with Clinical Phenotype in Factor XI Deficiency and Replacement Therapy

Highly Efficient Cardiac Differentiation and Maintenance by Thrombin-Coagulated Fibrin Hydrogels Enriched with Decellularized Porcine Heart Extracellular Matrix

Philippe Renaud, Thomas Michael Braschler, Fatemeh Navaee

Biochemical and biophysical properties instruct cardiac tissue morphogenesis. Here, we are reporting on a blend of cardiac decellularized extracellular matrix (dECM) from porcine ventricular tissue and fibrinogen that is suitable for investigations employi ...

MDPI2023

Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs

Christian Heinis, Jonas Alfred Karl Wilbs, Simon Jan Middendorp, Xudong Kong, Christina Lamers, Patrick Andreas Gonschorek

Inhibiting thrombosis without generating bleeding risks is a major challenge in medicine. A promising solution may be the inhibition of coagulation factor XII (FXII), because its knock-out or inhibition in animals reduced thrombosis without causing abnorma ...

Nature Research2020

De novo development of proteolytically resistant therapeutic peptides for oral administration

Christian Heinis, Florence Pojer, Luciano Andres Abriata, Xudong Kong, Kaycie Marie Butler, Vanessa Carle, Jun Moriya

The oral administration of peptide drugs is hampered by their metabolic instability and limited intestinal uptake. Here, we describe a method for the generation of small target-specific peptides (less than 1,600 Da in size) that resist gastrointestinal pro ...

2020

Development of cyclic peptide inhibitors of coagulation factor XIa for safer anticoagulation

Vanessa Carle

Hemostasis is a complex physiological process responsible for the prevention of blood loss caused by vascular injury. The dysregulation of this delicate mechanism can lead to thromboembolic diseases, the leading cause of death worldwide. Anticoagulants are ...

EPFL2019

Development of cyclic peptide inhibitors of coagulation factor XII and matrix metalloproteinase 2

Jonas Alfred Karl Wilbs

Peptides represent a promising molecular class for drug development. They combine several strengths of small molecules (e.g. efficient tissue diffusion, low immunogenicity and access to chemical synthesis) and key properties of biologics such as monoclonal ...

EPFL2018

Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity

Christian Heinis, Jonas Alfred Karl Wilbs, Simon Jan Middendorp

Factor XII (FXII) is a plasma protease that has emerged in recent years as a potential target to treat or prevent pathological thrombosis, to inhibit contact activation in extracorporeal circulation, and to treat the swelling disorder hereditary angioedema ...

2017

Microdevice for Sedimentation-based Separation of Blood Microsamples at the Point of Collection

David Forchelet

Laboratory blood testing plays a central role in current diagnostics and therapeutical decisions. Thus, errors have a direct impact on care quality and cost. The majority of errors occur in the pre-analytical phase, when samples are collected, stored and p ...

EPFL2017

Improving the binding affinity of in-vitro-evolved cyclic peptides by inserting atoms into the macrocycle backbone

Christian Heinis, Jonas Alfred Karl Wilbs, Simon Jan Middendorp

Cyclic peptides binding to targets of interest can be generated efficiently with powerful in vitro display techniques, such as phage display or mRNA display. The cyclic peptide libraries screened with these methods are generated by altering in a combinator ...

2016

A Synthetic Factor XIIa Inhibitor Blocks Selectively Intrinsic Coagulation Initiation

Christian Heinis, Shiyu Chen, Vanessa Baeriswyl, Alessandro Zorzi, Luca Bologna

Coagulation factor XII (FXII) inhibitors are of interest for the study of the protease in the intrinsic coagulation pathway, for the suppression of contact activation in blood coagulation assays, and they have potential application in antithrombotic therap ...

American Chemical Society2015

Portable Technologies for Self-Monitoring of Coagulation Time: A Review

Philippe Renaud, Lynda Metref

Anti-coagulation treatments are required for medical conditions that become more and more frequent with the ageing of the population in developed countries (atrial fibrillation, deep-venous thrombosis, heart prosthetic valves, etc.). These treatments gener ...

2012

Force spectroscopy of the fibrin(ogen) - Fibrinogen interaction

Giovanni Dietler

Fibrin aggregation is of vital importance in many physiological and pathological processes, such as blood coagulation, wound healing, and thrombosis. In the present study, we investigated the forces involved in the initial steps of the fibrinogen fibrin ag ...

2008

Coagulants of Moringa Oleifera Lam. seeds : purification & characterisation

Water has been declared a human right by the United Nations, thus urging countries who have ratified the International Covenant on Economic, Social and Cultural Rights to ensure supply with drinking water for their populations1. However, supply of drinking ...

EPFL2005

Enzymatic incorporation of bioactive peptides into fibrin matrices enhances neurite extension

Patrick Aebischer, Jeffrey Alan Hubbell

Fibrin plays an important role in wound healing and regeneration, and enjoys widespread use in surgery and tissue engineering. The enzymatic activity of Factor XIIIa was employed to covalently incorporate exogenous bioactive peptides within fibrin during c ...

2000